We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
News

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
News

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nuvo Research Announces Collaboration to Develop Topical Dermatology Products"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nuvo Research Inc. has announced a collaboration involving Ferndale Laboratories, Inc. (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE™) technology.

"This exciting opportunity demonstrates how Nuvo can leverage one of our four proprietary technologies that enhances the delivery of active drugs into or through the skin," said Dan Chicoine, Nuvo's Chairman and Co-CEO. "This agreement validates our patented drug delivery platforms and highlights our ability to expand our development product pipeline through strategic collaborations with partners who will fund the costs of clinical development."

Under the terms of the collaboration agreement, Nuvo will utilize its proprietary MMPE technology to formulate two patented topical dermatology product candidates.

Once the formulations are complete, Ferndale in collaboration with the CRO, will oversee and fund the formulations' advancement through Phase 2 clinical studies. It is anticipated that the product candidates will then be made available for out-licensing.

Licensing revenues, including upfront payments, milestone payments and royalties will be shared by the parties based on a formula that includes compensation to Nuvo for contributing the patented formulations.

Advertisement